🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 10 of 173

  1. US 12109228

    Treatment of neurodegenerative disease with sodium chlorite

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12109236

    Manipulating ARID5B expression in immune cells to promote metabolism, survival, and function

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12109231

    Treatment of neurodegenerative disease with sodium chlorite

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12109239

    Methods for production of human hemogenic endothelial cells from pluripotent stem cells and compositions thereof

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12109296

    Peptide exhibiting wrinkle-improving activity and uses thereof

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12109204

    Methods for treating muscular dystrophies

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12109230

    Treatment of neurodegenerative disease with sodium chlorite

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12109224

    USB1 directed regulation of miRNAs related hematopoietic differentiation and affected in multiple forms of leukemia

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12102668

    Process, tube and device for the preparation of wound healant composition

    Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12102617

    Antimicrobial compositions containing a synergistic combination of activated creatinine and an imidazole antifungal agent

    Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12103958

    Lymphocyte function-associated antigen 3 (LFA3) variant polypeptides and methods of use thereof to treat CD2-mediated immune diseases, disorders or conditions

    Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12104181

    Compositions and methods for treating viral infections targeting TRIM7

    Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12098182

    Polypeptides, cells, and methods involving engineered CD16

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12097262

    mTORC1 inhibitors

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12097291

    Thermostable vaccine compositions and methods of preparing same

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12097290

    Membrane encapsulated nanoparticles and method of use

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12098385

    Gene therapy strategy to restore cardiac electrical and structural function in arrhythmogenic right ventricular cardiomyopathy

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12098118

    Analgesic and anti-addictive compositions for treatment of chronic pain and opioid addiction

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12097223

    Mesenchymal stromal cells and uses related thereto

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12098138

    Substituted pyridinyl azetidinone derivatives for use in treating cancer and other diseases

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12097213

    Sequential treatment of cancers using 6-thio-dG, checkpoint inhibitors and radiation therapy

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12090170

    Methods of treating glioblastomas

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12091387

    Quinoline cGAS antagonist compounds

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12090142

    Combination therapy for the treatment of cancer

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12090206

    Compositions comprising tri- and penta-block synthetic copolypeptide hydrogels

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12089574

    Humanized skeletal muscle

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12090175

    Compositions and methods for tissue repair with extracellular matrices

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12091486

    Block copolymer and micelle compositions and methods of use thereof

    Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12084691

    Modulating human Cas9-specific host immune response

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12084677

    Methods of recellularizing a tissue or organ for improved transplantability

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12084490

    Antibody based reagents that specifically recognize toxic oligomeric forms of tau

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12084727

    Microbiome markers and therapies for autism spectrum disorders

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12083137

    Triazole bisphosphonate geranylgeranyl diphosphate synthase inhibitors

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12084403

    Linkers for antibody drug conjugates

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12083162

    Universal nanosponge for treating respiratory viral infection

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12084468

    Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12084514

    Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12084481

    HV1 modulators and uses

    Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12076330

    Inhibition of lipofuscin aggregation by molecular tweezers

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12076301

    Engaging the cervical spinal cord circuitry to re-enable volitional control of hand function in tetraplegic subjects

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12076397

    Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12076329

    Compositions and methods for enhancing visual function

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12077760

    DNA aptamers and use thereof for the treatment of cancer

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12077507

    Compositions and methods for treating cancer

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12077540

    Substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3'-indoline]-2',5(3H)-dione analogues

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12076332

    Treatment of lysosomal storage disorders

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12077772

    Transgene cassettes, AAV vectors and AAV viral vectors for the expression of human codon-optimized SLC6A1

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12076328

    Pharmaceutical compositions of niclosamide

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.